Korea Arlico Pharm Co.,Ltd.
Financials
Valuation Metrics
Korea Arlico Pharm Co.,Ltd.'s Market Cap is ₩381B. At end of 2025 it was ₩655B. Ranked #1920 of 2,436 in KR market (top 79%), #1197 of 1,649 on KOSDAQ (top 73%), #209 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 89%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 38.09B KRW | KR#1,920/2,436 Sec#209/234 |
| Revenue | 199.14B KRW | KR#1,018/2,436 Sec#60/234 |
| Net Income | -1.62B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 170.71B KRW | KR#1,379/2,436 Sec#109/234 |
| Net Assets | 76.51B KRW | KR#1,586/2,436 Sec#132/234 |
| Employees | 242 | KR#939/2,436 Sec#82/234 |
| Value | ||
| P/B | 0.50x | KR#797/2,436 Sec#33/234 |
| P/S | 0.19x | KR#348/2,436 Sec#5/234 |
| FCF Yield | 18.07% | KR#372/2,436 Sec#6/234 |
| Profitability | ||
| ROE | -2.12% | KR#1,624/2,436 Sec#114/234 |
| ROA | -0.95% | KR#1,592/2,436 Sec#111/234 |
| Op. Margin | -0.89% | KR#1,675/2,436 Sec#119/234 |
| Revenue Growth | -4.09% | KR#1,658/2,436 Sec#155/234 |
| Earnings Growth | -255.54% | KR#1,536/2,436 Sec#100/234 |
| Financial Health | ||
| Debt Ratio | 223.12% | KR#1,862/2,436 Sec#202/234 |
| Total Debt | 11.82B KRW | KR#1,563/2,436 Sec#143/234 |
| FCF | 6.88B KRW | KR#817/2,436 Sec#52/234 |
| Cash | 17.87B KRW | KR#1,311/2,436 Sec#101/234 |
| Current Ratio | 1.09x | KR#1,719/2,436 Sec#174/234 |
| Dividend | ||
| Div. Yield | 3.13% | KR#634/2,436 Sec#29/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -44.78% | KR#1,958/2,436 Sec#175/234 |
| 1M Return | 0.00% | KR#874/2,436 Sec#77/234 |
| From 52W High | -56.86% | KR#1,555/2,436 Sec#134/234 |
| 1Y MDD | -56.83% | KR#1,243/2,436 Sec#102/234 |
| Trading | ||
| Volume | 30,459 shares | KR#1,636/2,436 Sec#161/234 |
| Foreign Own. | 4.40% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -106 KRW | KR—/2,436 Sec—/234 |
| BPS | 5,096 KRW | KR#1,420/2,436 Sec#103/234 |
Company Info
Alico Pharmaceutical, established in 1992, manufactures and sells pharmaceuticals, having been listed on the KOSDAQ market in 2018. Its core businesses encompass domestic pharmaceutical sales, contract manufacturing organization (CMO), export of pharmaceuticals and goods, and the development and sale of medical devices, health functional foods, and cosmetics. The company has achieved external growth and profitability by focusing on profitable specialized pharmaceutical renewals, efficient production systems, and a low-cost, high-efficiency sales network. Alico Pharmaceutical is headquartered in Seocho-gu, Seoul.